Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452842 | 0.88 | ROCK1 (0.56) | ROCK1NPC1RAB9AROCK2PARP1 | |
| SCHEMBL19902318 | 0.82 | ROCK1 (0.55) | ROCK1NPC1RAB9AROCK2PARP1 | |
| SCHEMBL19902473 | 0.82 | NPC1 (0.46) | ROCK1NPC1RAB9AROCK2PARP1 | |
| SCHEMBL19902689 | 0.79 | ROCK2 (0.46) | ROCK1NPC1RAB9AROCK2SMYD3 | |
| SCHEMBL19902546 | 0.78 | ROCK2 (0.61) | ROCK1NPC1RAB9AROCK2 | |
| SCHEMBL19902690 | 0.77 | SMN1; SMN2 (0.44) | ROCK1NPC1RAB9AROCK2PARP1 | |
| SCHEMBL19902337 | 0.76 | NPC1 (0.57) | ROCK1NPC1RAB9AROCK2 | |
| SCHEMBL1789261 | 0.76 | ATM (0.50) | ROCK1NPC1RAB9AROCK2PARP1 | |
| SCHEMBL17311624 | 0.74 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL19902393 | 0.74 | ROCK2 (0.41) | ROCK1NPC1RAB9AROCK2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885NPC1 2709/4885RAB9A 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.